## Supplementary Table 1. Baseline characteristics

|  |  |  |  |
| --- | --- | --- | --- |
|  | **TMF 25 mg** | **TDF 300 mg** | **Total** |
|  | **(N = 666)** | **(N = 336)** | **(N = 1002)** |
| Age (years) | 35 (29-44) | 35 (28-45) | 35 (29-44) |
| Male | 480 (72.1%) | 243 (72.3%) | 723 (72.2%) |
| Body mass index (kg/m2) | 23.2 (21.21-25.48) | 23.1 (21.11-25.53) | 23.2 (21.16-25.51) |
| HBeAg-positive | 486 (73.0%) | 246 (73.2%) | 732 (73.0%) |
| HBV DNA (log10 IU/mL) |  | | |
| Pooled | 7.28 (5.86-8.23) | 7.34 (5.86-8.23) | 7.31 (5.86-8.23) |
| HBeAg-positive | 7.93 (6.61-8.23) | 7.91 (6.75-8.23) | 7.92 (6.68-8.23) |
| HBeAg-negative | 5.82 (5.06-6.58) | 5.72 (5.08-6.54) | 5.78 (5.06-6.58) |
| HBV DNA ≥ 8 log10 IU/mL |  | | |
| Pooled | 253 (37.9%) | 128 (38.1%) | 381 (38.0%) |
| HBeAg-positive | 244/486 (50.2%) | 123/246 (50.0%) | 367/732 (50.1%) |
| HBeAg-negative | 9/180 (5.0%) | 5/90 (5.6%) | 14/270 (5.2%) |
| HBV genotype |  | | |
| B | 285 (42.8%) | 143 (42.6%) | 428 (42.7%) |
| C | 372 (55.9%) | 187 (55.7%) | 559 (55.8%) |
| Others | 9 (1.4%) | 6 (1.8%) | 15 (1.5%) |
| ALT (U/L) |  | | |
| Pooled | 98.6 (65-163) | 99.95 (62.7-157.5) | 99 (64-162) |
| HBeAg-positive | 104.5 (68-167.3) | 101.45 (69-164) | 103.35 (68-167) |
| HBeAg-negative | 87.5 (60.75-153.1) | 82.5 (53-146.2) | 84.8 (58.3-148) |
| ALT > 1 ULNa at baseline (N/%) |  | | |
| Pooled | 614 (92.2%) | 297 (88.4%) | 911 (90.9%) |
| HBeAg-positive | 451/486 (92.8%) | 226/246 (91.9%) | 677/732 (92.5%) |
| HBeAg-negative | 163/180 (90.6%) | 71/90 (78.9%) | 234/270 (86.7%) |
| Previous cirrhosisb |  | | |
| Pooled | 125 (18.8%) | 66 (19.6%) | 191 (19.1%) |
| HBeAg-positive | 95/486 (19.5%) | 48/246 (19.5%) | 143/732 (19.5%) |
| HBeAg-negative | 30/180 (16.7%) | 18/90 (20.0%) | 48/270 (17.8%) |
| Treated for HBVc |  |  |  |
| Any interferon | 46 (6.9%) | 20 (6.0%) | 66 (6.6%) |
| Any nucleot(s)ide analogs | 190 (28.5%) | 96 (28.6%) | 286 (28.5%) |
| Entecavir | 100 (15.0%) | 58 (17.3%) | 158 (15.8%) |
| Adefovir | 49 (7.4%) | 23 (6.8%) | 72 (7.2%) |
| TDF | 37 (5.6%) | 10 (3.0%) | 47 (4.7%) |
| Nonindexed eGFR by CKD-EPIscr equation (mL/min) | 111.73 | 111.47 | 111.70 |
| Creatinine clearance by cg equation (mL/min) | 115.51 | 114.33 | 114.85 |
| BMD by DXA (g/cm²) |  | | |
| Total hip | 0.94 (0.86-1.02) | 0.94 (0.86-1.02) | 0.94 (0.86-1.02) |
| Femur neck | 0.84 (0.75-0.94) | 0.84 (0.75-0.95) | 0.84 (0.75-0.94) |
| Lumbar spine (L1-L4) | 1 (0.91-1.11) | 1 (0.92-1.1) | 1 (0.92-1.11) |
| Osteopenia by ISCD standard | 85/664 (12.8%) | 34/331 (10.3%) | 119/995 (12.0%) |
| Osteoporosis by ISCD standard | 6/664 (0.9%) | 3/331 (0.9%) | 9/995 (0.9%) |
| Comorbiditiesd |  |  |  |
| Diabetes mellitus | 18 (2.7%) | 8 (2.4%) | 26 (2.6%) |
| Dyslipidemia | 126 (18.9%) | 48 (14.3%) | 174 (17.4%) |
| Hypertension | 38 (5.7%) | 21 (6.3%) | 59 (5.9%) |
| Cardiovascular disease | 54 (8.1%) | 27 (8.0%) | 81 (8.1%) |
| Upper respiratory tract infection | 3 (0.5%) | 6 (1.8%) | 9 (0.9%) |
| Nasopharyngitis | 9 (1.4%) | 3 (0.9%) | 12 (1.2%) |
| Hepatic steatosis | 156 (23.4%) | 73 (21.7%) | 229 (22.9%) |
| Hyperuricemia | 37 (5.6%) | 25 (7.4%) | 62 (6.2%) |
| Hypertriglyceridemia | 11 (1.7%) | 1 (0.3%) | 12 (1.2%) |
| Data are *n* (%), *n*/N (%) or median (IQR). CKD-EPIscr, chronic kidney disease epidemiology collaboration serum creatinine; DXA, dual energy x-ray absorptiometry; eGFR, estimated glomerular filtration rate; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ULN, upper limit of normal range. aThe ALT ULN was based American Association for the Study of Liver Diseases (AASLD) guidance, which is 35 U/L for male and 25 U/L for female; bPatients were diagnosed as cirrhosis by transient elastography under different ALT levels; cThe proportion of treated HBV patients were similar in HBeAg-positive and -negative population; dComorbidities were collected according to medical history. | | | |